The molecular biology of vestibular schwannomas: Dissecting the pathogenic process at the molecular level

Otology and Neurotology

Volumn 27, Issue 2, 2006, Pages 197-208

  Neff, Brian A ^a   Welling, D Bradley ^a,b   Akhmametyeva, Elena ^a   Chang, Long Sheng ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Acoustic neuroma; Merlin; Neurofibromatosis type 2; NF2 gene; Vestibular schwannoma

Indexed keywords

DNA; GENE PRODUCT; KI 67 ANTIGEN; MERLIN; MESSENGER RNA; NEUROFIBROMATOSIS TYPE 2 PROTEIN; PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

CELL TRANSFORMATION; CORRELATION ANALYSIS; GENE FUNCTION; GENE LOCATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR BIOLOGY; NEURILEMOMA; NEUROFIBROMATOSIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; RNA SPLICING; SIGNAL TRANSDUCTION; VESTIBULAR SCHWANNOMA; VESTIBULAR SYSTEM;

ALTERNATIVE SPLICING; ANIMALS; CHROMOSOMES, HUMAN, PAIR 22; DISEASE MODELS, ANIMAL; GENES, NEUROFIBROMATOSIS 2; GENETIC SCREENING; GENETIC TESTING; HUMANS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MICE; MUTATION; NEUROFIBROMIN 2; NEUROMA, ACOUSTIC; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 33645051945     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/01.mao.0000180484.24242.54     Document Type: Review

References (114)

1. Howitz MF, Johansen C, Tos M, et al. Incidence of vestibular schwannoma in Denmark, 1977-1995. Am J Otol 2000;21: 690-4.
2. Anderson TD, Loevner LA, Bigelow DC, et al. Prevalence of unsuspected acoustic neuroma found by magnetic resonance imaging. Otolaryngol Head Neck Surg 2000;122:643-6.
3. Bull. World Health Org. Prevention and control of neurofibromatosis: Memorandum from a joint WHO/NNFF meeting. Bull World Health Org 1992;70:173-82.
4. Kanter WR, Eldridge R, Fabricant R, et al. Central neurofibromatosis with bilateral acoustic neuroma: genetic, clinical and biochemical distinctions from peripheral neurofibromatosis. Neurology 1980;30:851-9.
5. Martuza RL, Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med 1988;318:684-8.
6. Baser ME, Friedman JM, Wallace AJ, et al. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 2002;59:1759-65.
7. Evans DGR, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom: I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 1992;29:841-6.
8. Wishart JH. Case of tumors in the skull, dura mater, and brain. Edinburgh Med Surg J 1822;18:393-7.
9. Gardner WJ, Frazier CH. Bilateral acoustic neurofibromatosis: a clinical study and field survey of a family of five generations with bilateral deafness in thirty-eight members. Arch Neurol Psychiatry 1930;23:266-302.
10. Ruggieri M, Huson SM. The clinical and diagnostic implications of mosaicism in neurofibromatosis. Neurology 2001;56:1433-43.
11. Kluwe L, Mautner V, Heinrich B. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 2003;40:109-14.
12. Moyhuddin A, Baser MG, Watson C. Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet 2003;40:459-63.
13. MacCollin M, Willett C, Heinrich B, et al. Familial schwannomatosis: exclusion of the NF2 locus as the germline event. Neurology 2003;60:1968-74.
14. Charabi S, Tos M, Thomsen J, et al. Cystic vestibular schwannoma: clinical and experimental studies. Acta Otolaryngol 2000;543(Suppl):11-3.
15. Charabi S, Tos M, Borgesen SE, et al. Cystic acoustic neuromas: results of translabyrinthine surgery. Arch Otolaryngol Head Neck Surg 1994;120:1333-8.
16. Fundova P, Charabi S, Tos M, et al. Cystic vestibular schwannoma: surgical outcome. J Laryngol Otol 2000;114:935-9.
17. Pendl G, Ganz JC, Kitz K, et al. Acoustic neurinomas with macrocysts treated with gamma knife radiosurgery. Stereotact Funct Neurosurg 1995;66(Suppl):103-11.
18. Shirato H, Sakamoto T, Takeichi N, et al. Fractionated stereotactic radiotherapy for vestibular schwannoma (VS): comparison between cystic-type and solid-type VS. Int J Radiat Oncol Biol Phys 2000;48:1395-401.
19. Welling DB, Lasak JM, Akhmametyeva EM, et al. cDNA microarray analysis of vestibular schwannomas. Otol Neurotol 2002;23:736-48.
20. Lasak JM, Welling DB, Salloum M, et al. Deregulation of the pRb-CDK pathway in vestibular schwannomas. Laryngoscope 2001;112:1555-61.
21. Rouleau GA, Wertelecki W, Haines JL, et al. Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature 1987;329:246-8.
22. Wertelecki W, Rouleau GA, Superneau DW, et al. Neurofibromatosis 2: clinical and DNA linkage studies of a larger kindred. N Engl J Med 1988;319:278-83.
23. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 1993;363:515-21.
24. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel Moesin-, Exrin-, Radixin-like gene is a candidate for the neurofibromatosis 2 tumor-suppressor. Cell 1993;72:791-800.
25. Welling DB, Guida M, Goll F, et al. Mutational spectrums in the neurofibromatosis type 2 gene in sporadic and familial schwannomas. Hum Genet 1996;98:189-93.
26. Merel P, Khe HX, Sanson M, et al. Screening for germ-line mutations in the NF2 gene. Genes Chromosome Cancer 1995;12:117-2.
27. MacCollin M, Ramesh V, Jacoby LB, et al. Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet 1994;55:314-20.
28. Jacoby LB, MacCollin M, Louis DN, et al. Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet 1994;3:413-9.
29. Kluwe L, Bayer S, Baser ME, et al. Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes. Hum Genet 1996;98:534-8.
30. Parry DM, MacCollin MM, Kaiser-Kupfer MI, et al. Germline mutations in the neurofibromatosis 2 gene: correlation with disease severity and retinal abnormalities. Am J Hum Genet 1996;59:529-3.
31. Ruttledge MH, Andermann AA, Phelan CM, et al. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 1996;59:331-42.
32. Mautner VF, Baser ME, Kluwe L. Phenotypic variability in two families with novel splice-site and frameshift NF2 mutations. Hum Genet 1996;98:203-6.
33. Zucman-Rossi J, Legoix P, Der Sarkissian H, et al. NF2 gene in neurofibromatosis type 2 patients. Hum Mol Genet 1998;7:2095-101.
34. Evans DG, Trueman L, Wallace A, et al. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet 1998;35:450-5.
35. Antinheimo J, Sallinen SL, Sallinen P, et al. Genetic aberrations in sporadic and neurofibromatosis 2 (NF2)-associated schwannomas studied by comparative genomic hybridization (CGH). Acta Neurochir (Wien) 2000;142:1099-104.
36. Hung G, Faudoa R, Baser ME, et al. Neurofibromatosis 2 phenotypes and germ-line NF2 mutations determined by an RNA mismatch method and loss of heterozygosity analysis in NF2 schwannomas. Cancer Genet Cytogenet 2000;118:167-8.
37. Welling DB. Clinical manifestations of mutations in the neurofibromatosis type 2 gene in vestibular schwannomas (acoustic neuromas). Laryngoscope 1998;108:178-89.
38. Jacoby LB, MacCollin M, Barone R, et al. Frequency and distribution of NF2 mutations in schwannomas. Genes Chromosomes Cancer 1996;17:45-55.
39. Merel P, Hoang-Xuan K, Sanson M, et al. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosomes Cancer 1995;13:1211-6.
40. Bianchi AB, Hara T, Ramesh V, et al. Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat Genet 1994;6:185-92.
41. Ruttledge MH, Sarrazin J, Rangaratnam S, et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 1994;6:180-4.
42. Deguen B, Goutebroze L, Giovannini M, et al. Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene. Int J Cancer 1998;77:554-60.
43. Irving RM, Moffat DA, Hardy DG, et al. Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma. Hum Mol Genet 1994;3:347-50.
44. Sainz J, Figueroa K, Baser ME, et al. High frequency of nonsense mutations in the NF2 gene caused by C to T transitions in five CGA codons. Hum Genet 1995;4:137-9.
45. Sainz J, Huynh DP, Figueroa K, et al. Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. Hum Mol Genet 1994;3:885-91.
46. Gutmann DH, Geist RT, Xu H, et al. Defects in neurofibromatosis 2 protein function can arise at multiple levels. Hum Mol Genet 1998;7:335-4.
47. Stokowski RP, Cox DR. Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations. Am J Hum Genet 2000;66:873-91.
48. Gutmann DH, Hirbe AC, Haipek CA. Functional analysis of neurofibromatosis 2 (NF2) missense mutations. Hum Mol Genet 2001;10:1519-2.
49. Bruder DEG, Kirvela C, Tapia-Paez I, et al. High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Hum Mol Genet 2001;10:271-82.
50. Bruder CE, Ichimura K, Blennow E, et al. Severe phenotype of neurofibromatosis type 2 in a patient with a 7.4-MB constitutional deletion on chromosome 22: possible localization of a neurofibromatosis type 2 modifier gene? Genes Chromosomes Cancer 1999;25:184-90.
51. Kino T, Takeshima H, Nakao M, et al. Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma. Genes Cells 2001;6:441-54.
52. Chang LS, Akhmametyeva EM, Wu Y, et al. Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts. Genomics 2002;79:63-76.
53. Hitotsumatsu T, Kitamoto T, Iwaki T, et al. An exon 8-spliced out transcript of neurofibromatosis 2 gene is constitutively expressed in various human tissues. J Biochem 1994;116:1205-7.
54. Pykett MJ, Murphy M, Harnish PR, et al. The neurofibromatosis type 2 tumor suppressor gene encodes multiple alternatively spliced transcripts. Hum Mol Genet 1994;3:559-64.
55. Giovannini M, Robanus-Maandag E, Niwa-Kawakita M, et al. Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev 1999;13:978-86.
56. Welling DB, Akhmametyeva EM, Daniels RL, et al. Analysis of the human neurofibromatosis type 2 gene promoter and its expression. Otolaryngol Head Neck Surg 2000;123:413-8.
57. Chishti AH, Kim AC, Marfatia SM, et al. The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane. Trends Biochem Sci 1998;23:281-2.
58. Bretscher A, Chambers D, Nguyen R, et al. ERM-Merlin and EBP50 protein families in plasma membrane organization and function. Annu Rev Cell Dev Biol 2000;16:113-43.
59. Turunen O, Wahlstrom T, Vaheri A. Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family. J Cell Biol 1994;126:1445-53.
60. Roy C, Martin M, Mangeat P. A dual involvement of the amino-terminal domain of ezrin in F- and G-actin binding. J Biol Chem 1997;272:20088-95.
61. Gonzalez-Agosti C, Xu L, Pinney D, et al. The merlin tumor suppressor localizes preferentially in membrane ruffles. Oncogene 1996;13:1239-47.
62. Pelton PD, Sherman LS, Rizvi TA, et al. Ruffling membrane, stress fiber, cell spreading, and proliferation abnormalities in human schwannoma cells. Oncogene 1998;17:2195-209.
63. Deguen B, Merel P, Goutebroze L, et al. Impaired interaction of naturally occurring mutant NF2 protein with actin-based cytoskeleton and membrane. Hum Mol Genet 1998;7:217-26.
64. Lutchman M, Rouleau GA. The neurofibromatosis type 2 gene product, schwannomin, suppresses growth of NIH 3T3 cells. Cancer Res 1995;55:2270-4.
65. Tikoo A, Varga M, Ramesh V, et al. An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin). J Biol Chem 1994;269:23387-90.
66. McClatchey AI, Saotome I, Mercer K, et al. Mice heterozygous for a mutation at the NF2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev 1998;12:1121-33.
67. McClatchey AI, Saotome I, Ramesh V, et al. The NF2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev 1997;11:1253-65.
68. Giovannini M, Robanus-Maandag E, van der Valk M, et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 2000;14:1617-30.
69. Shaw RJ, Paez JG, Curto M, et al. The NF2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell 2001;1:63-72.
70. Fernandez-Valle C, Tang Y, Ricard J, et al. Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat Genet 2000;31:354-62.
71. Gronholm M, Vossebein L, Carlson CR, et al. Merlin links to the cAMP neuronal signaling pathway by anchoring the R1 beta subunit of protein kinase A. J Biol Chem 2003;278:41167-72.
72. Kissil JL, Wilker EW, Johnson KC, et al. Merlin, the product of the NF2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, PAK1. Mol Cell 2003;12:841-9.
73. Takeshima H, Izawa I, Lee PS, et al. Detection of cellular proteins that interact with the NF2 tumor suppressor gene product. Oncogene 1994;9:2135-44.
74. Sainio M, Zhao F, Heiska L, et al. Neurofibromatosis 2 tumor suppressor protein co-localizes with ezrin and CD44 and associates with actin-containing cytoskeleton. J Cell Sci 1997;110:2249-60.
75. Huang L, Ichimaru E, Pestonjamasp K, et al. Merlin differs from moesin in binding to F-actin and in its intra- and intermolecular interactions. Biochim Biophys Res Commun 1998;248:548-53.
76. Murthy A, Gonzalez-Agosti C, Cordero E, et al. NHE-RF, a regulatory cofactor for Na(+)-H+ exchange, is a common interactor for merlin and ERM (MERM) proteins. J Biol Chem 1998;273:1273-6.
77. Obremski VJ, Hall AM, Fernandez-Valle C. Merlin, the neurofibromatosis type 2 gene product, and β1 integrin associate in isolated and differentiating Schwann cells. J Neurobiol 1998;37:487-501.
78. Scoles DR, Huynh DP, Morcos PA, et al. Neurofibromatosis 2 tumor suppressor schwannomin interacts with βII-spectrin. Nat Genet 1998;18:354-9.
79. Scoles DR, Huynh DP, Chen MS, et al. The neurofibromatosis 2 tumor suppressor protein interacts with hepatocyte growth factor-regulated tyrosine kinase substrate. Hum Mol Genet 2000;9:1567-74.
80. Xu HM, Gutmann DH. Merlin differentially associates with the microtubule and actin cytoskeleton. J Neurosci Res 1998;51:403-15.
81. Goutebroze L, Brault E, Muchardt C, et al. Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins. Mol Cell Biol 2000;20:1699-712.
82. Herrlich P, Morrison H, Sleeman J, et al. CD44 acts both as a growth and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci 2000;910:106-18.
83. Sherman L, Sleeman J, Herrlich P, et al. Hyaluronate receptors: key players in growth, differentiation, migration, and tumor progression. Curr Opin Cell Biol 1994;6:726-33.
84. Morrison H, Sherman LS, Legg J, et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 2001;15:968-80.
85. Xiao GH, Beeser A, Chernoff J, et al. P21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem 2002;277:883-6.
86. Kissil JL, Johnson KC, Eckman MS, et al. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem 2002;277:10394-9.
87. Bretscher A, Reczek D, Berryman M. Ezrin: a protein requiring conformational activation to link microfilaments to the plasma membrane in the assembly of cell surface structures. J Cell Sci 1997;110:3011-8.
88. Hirao M, Sato N, Kondo T, et al. Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway. J Cell Biol 1996;135:37-51.
89. Gutmann DH, Sherman L, Seftor L, et al. Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesion and spreading. Hum Mol Genet 1999;8:267-75.
90. Gutmann DH, Haipek CA, Burke SP, et al. The NF2 interactor, hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), associates with merlin in the 'open' conformation and suppresses cell growth and motility. Hum Mol Genet 2001;10:825-34.
91. Pearson MA, Reczek D, Bretscher A, et al. Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell 2000;101:259-70.
92. Komada M, Kitamura N. Growth factor-induced tyrosine phosphorylation of HRS, a novel 115- kilodalton protein with a structurally conserved putative zinc finger domain. Mol Cell Biol 1995;15:6213-21.
93. Niemczyk K, Vaneecloo FN, Lecomte MH, et al. Correlation between Ki-67 index and some clinical aspects of acoustic neuromas (vestibular schwannomas). Otolaryngol Head Neck Surg 2000;123:779-83.
94. Light JP, Roland JT Jr, Fishman A, et al. Atypical and low-grade malignant vestibular schwannomas: clinical implications of proliferative activity. Otol Neurotol 2001;22:922-7.
95. Chen JM, Houle S, Ang LC, et al. A study of vestibular schwannomas using positron emission tomography and monoclonal antibody Ki-67. Am J Otol 1998;19:840-5.
96. Kesterson L, Shelton C, Dressler L, et al. Clinical behavior of acoustic tumors: a flow cytometric analysis. Arch Otolaryngol Head Neck Surg 1993;119:269-71.
97. Charabi S, Klinken L, Tos M, et al. Histopathology and growth pattern of cystic acoustic neuromas. Laryngoscope 1994;104:1348-52.
98. Antinheimo J, Haapasalo H, Seppala M, et al. Proliferative potential of sporadic and neurofibromatosis 2-associated schwannomas as studied by MIB-1 (Ki-67) and PCNA labeling. J Neuropathol Exp Neurol 1995;54:776-82.
99. Cardillo MR, Filipo R, Monini S, et al. Transforming growth factor-beta1 expression in human acoustic neuroma. Am J Otol 1999;20:65-8.
100. Evans DGR, Sainio M, Baser ME. Neurofibromatosis type 2. J Med Genet 2000;37:897-904.
101. Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996;38:880-85.
102. Sainio M, Strachan T, Blomstedt G, et al. Presymptomatic DNA and MRI diagnosis of neurofibromatosis 2 with mild clinical course in an extended pedigree. Neurology 1995;45:1314-22.
103. Lander ES, Lenton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921.
104. Lockhart DJ, Winzeler EA. Genomics, gene expression, and DNA arrays. Nature 2000;405:827-36.
105. DeRisi JL, Iyer VR, Brown PO. Exploring the metabolic and genetic control of gene expression on a genomic scale. Science 1997;278:680-6.
106. Zhang DH, Salto-Tellez M, Chiu LL, et al. Tissue microarray study for classification of breast tumors. Life Sci 2003;73:3189-99.
107. Nishizuku S, Chen ST, Gwadry FG, et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification, genomic, proteomic, and tissue array profiling. Cancer Res 2003;63:5243-50.
108. Alizadeh AA, Ross DT, Perou CM, et al. Towards a novel classification of human malignancies based on gene expression patterns. J Pathol 2001;195:41-52.
109. Jordan CT. Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia 2002;16:559-62.
110. Klausner RD. Cancer, genomics, and the National Cancer Institute. J Clin Invest 1999;104:S15-7.
111. Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junction. Genes Dev 2003;17:1090-1100.
112. Ryu CH, Kim SW, Lee KH, et al. The merlin tumor suppressor interacts with Ral guanine nucleotide dissociation stimulator and inhibits its activity. Oncogene 2005;24:5355-64.
113. Manchanda N, Lyubimova A, Ho HY, et al. The NF2 tumor suppressor Merlin and ERM proteins interact with N-WASP and regulate its actin polymerization function. J Biol Chem 2005;280:12517-22.
114. Rangwala R, Banine F, Borg JP, Sherman LS. Erbin regulates mitogen-activated protein (MAP) kinase activation and MAP kinase-dependent interactions between Merlin and adherens junction protein complexes in Schwann cells. J Biol Chem 2005;280:11790-7.